The Centers for Medicare & Medicaid Services has changed course on plans to appeal a court ruling that determined it must ...
The U.S. Centers for Medicare and Medicaid Services on Friday said it would not appeal a court order that it recalculate the ...
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
The new Trump administration should seize the opportunity to change the Medicare drug price negotiation program by ...
UnitedHealth (UNH) stock in focus as Medicare withdraws appeal over an unfavorable ruling related to the company's 2025-Star ...
CMS issued the industry-wide ratings the next month. Among large insurers, UnitedHealthcare experienced one of the most dramatic drops in scores. In its lawsuit, the UnitedHealth Group subsidiary ...
The General Enrollment Period provides an opportunity to make up for a past oversight — the failure to enroll in Part B.
In November, a federal judge ordered CMS to recalculate UnitedHealthcare's Medicare Advantage Star Ratings for the 2025 plan ...
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
The U.S. health agency, the Centers for Medicare & Medicaid Services (CMS), announced Tuesday that it will appeal a November 2024 ruling to the Fifth Circuit Court of Appeals. What Happened: In ...
As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback